CoronaSafe™ Test Kit – 40 Kits

COVID-19 Employee Antibody Screening Test

CoronaSafe™ is a finger prick COVID-19 antibody screening text which provides detection of COVID-19 antibodies from a single drop of blood within 10 minutes. It’s been proven in extensive clinical trials of 1,585 patients during the recent outbreak, with 98.02% clinical specificity,  98.81% sensitivity, and 96.85% accuracy.

CoronaSafe™ can detect the presence of two key lgG and lgM immunoglobin biomarkers of COVID-19. lgM levels in blood can rise quickly and can be detectable from 7+ days after infection, with lgG levels also rising after 7 days. CoronaSafe™ can detect both immunoglobin biomarkers, whilst helping to give an indication of the progress of infection, including previous infections which could indicate acquired immunity.

Please note: this screening test is for business / professional use only, not for members of the public 

Source: Sethuraman, N., Jeremiah, S. S. & Ryo, A. J. Am. Med. Assoc. 323, 2249–2251 (2020). Article

How To Use

1. Use the lancet/click device to prick thumb/finger

2. Collect drop of blood in the capillary tube

3. Eject the blood drop into the sample well

4. Add 3 drops of buffer to the sample well

5. Wait 10 minutes and observe the results

Interpreting The Results

• IgG and IgM POSITIVE – Indicates that it may be a recent infection with COVID-19

• IgG POSITIVE – Indicates that it may be a previous infection with COVID-19

• IgM POSITIVE – Indicates that it may be a recent infection with COVID-19

• NEGATIVE – Indicates that it may be no infection with COVID-19, or there is not enough detectable antibodies in the early infection

Credentials & Quality Assurance

The test is certified by ISO and has been registered with MHRA for sale in the UK for professional use.

• ISO 18113-2 Requirements for information of in vitro diagnostic (IVD) reagents for professional use

• ISO 18113-4 Requirements for information of in vitro diagnostic (IVD) reagents for self-testing

• ISO 14971, ISO 18113-2, EN 17511, ISO 15193, ISO 15194, ISO 23640, EN 13641, EN 1041, ISO 15223-1

Clinical Study Results

1. The clinical sensitivity of the product was 98.81% (95% CI: 97.25%, 99.61%) and the specificity was 98.02% (95% CI: 97.05%, 98.74%) in 1,585 clinical samples (421 positive and 1,164 negative).

2. The homologous serum/plasma, whole blood samples (125 positives and 78 negatives) of 203 subjects were compared. According to the results of the serum/plasma test, the results of the whole blood test were consistent: 96.85% (95% CI: 95.87%~97.60%)

Testimonials

“We’re implementing CoronaSafe Covid-19 antibody tests from Martek Marine because they’ll help us identify infected persons to prevent an outbreak within our crew and on our vessels”

Neil Burns, Managing Director
James Fisher Shipping Services

This test provides only preliminary test results and should not be used for confirmatory testing or as a sole basis for diagnosis. The results will have to be interpreted together with clinical presentation. Any reactive specimen with the COVID-19 IgG/IgM must be confirmed with an alternative testing method(s) and clinical findings.

Download:

Datasheet

FAQ

Quick User Guide